NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

DermaRite Industries is recalling certain lots of its over-the-counter soaps, antiseptics, and analgesics due to ...

Nyxoah SA may now help make dreams come true here in the U.S. with its FDA approval for the Genio system for the treatment of ...

A huge new international study has uncovered, for the first time, a weekly rhythm disturbance in one of the world’s most ...